A Pharma Franchise Distribution and Marketing Agreement is a commercial contract between a pharmaceutical company and a distributor, franchise partner or PCD partner that defines how the partner may purchase, promote, distribute and sell the company’s pharmaceutical products within an agreed territory.

It commonly deals with:

• Territory or monopoly rights
• Product range
• Purchase conditions
• Net rates and price revisions
• Payment terms
• Drug-licence requirements
• Stock and storage
• Promotional rights
• Trademark use
• Expiry and returns
• Quality complaints
• Product recalls
• Sales targets
• Confidentiality
• Term and renewal
• Termination
• Dispute resolution

The agreement protects both parties by recording what each party has actually agreed to do.

Quick Answer

A good PCD pharma agreement should clearly answer these questions:

1. Who are the parties?
2. Which products are covered?
3. Which territory is allotted?
4. Is the territory exclusive or non-exclusive?
5. What performance is required to retain monopoly rights?
6. What licences must the distributor maintain?
7. Who owns the trademarks?
8. At what rates will products be supplied?
9. Who pays GST and freight?
10. When does title/risk pass?
11. What is the payment or credit period?
12. What happens to expiry and damaged goods?
13. Who handles quality complaints and recalls?
14. Who approves promotional material?
15. How can the agreement be terminated?
16. What happens after termination?
17. How will disputes be resolved?

The agreement should be reviewed by a lawyer familiar with pharmaceutical distribution before execution, particularly when exclusivity, trademarks, credit, indemnities or large territories are involved.

Is a Pharma Franchise Agreement Compulsory?

There is no single special central statute called a “PCD Pharma Franchise Agreement Act.”

The commercial contract is principally governed by the general law of contracts and the pharmaceutical laws applicable to the activities performed by the parties.

Section 10 of the Indian Contract Act, 1872 deals with what agreements become contracts, while the Act also covers free consent, lawful consideration, performance and consequences of breach.

Even where a particular PCD arrangement could operate without a specially prescribed “franchise form,” putting the arrangement in writing is strongly advisable because verbal monopoly promises often create disputes concerning:

• Territory
• Product allocation
• Rates
• Targets
• Expiry
• Payment
• Trademark ownership

There is also an important distinction where the relationship is not merely distribution but a formal manufacturer–marketer arrangement. CDSCO’s G.S.R. 101(E) specifically introduced provisions concerning the definition, responsibilities and labelling requirements of marketers of drugs.

Pharma Franchise Agreement vs Manufacturer–Marketer Agreement

These are not necessarily the same document.

Pharma Franchise Distribution Agreement

Primarily deals with:

• Purchase
• Distribution
• Territory
• Monopoly
• Sales
• Payment
• Promotion

Example:

ABC Pharma → XYZ Distributor for Karnal district

Manufacturer–Marketer Agreement

Deals with the relationship where one entity manufactures the drug and another entity is identified as the marketer.

Example:

Manufactured by ABC Laboratories

Marketed by XYZ Healthcare Pvt. Ltd.

CDSCO’s G.S.R. 101(E) created specific regulatory provisions for marketers, including responsibility and labelling requirements.

Third-Party Manufacturing Agreement

Deals primarily with:

• Formula
• Manufacturing
• Batch size
• Quality
• Packaging
• testing
• Product permissions
• Artwork
• Delivery
• Manufacturing price

A PCD franchise agreement should therefore not automatically be used as a substitute for a third-party manufacturing agreement.

Who Are the Parties?

A typical agreement contains:

First Party

The pharmaceutical:

• Manufacturer
• Marketing company
• PCD company
• Brand owner
• Distributor appointing another distributor

Second Party

The:

• PCD franchisee
• Distributor
• Stockist
• Wholesaler
• Marketing partner

The legal names should match actual documents.

For example:

ABC Healthcare Private Limited

should not be casually written as:

ABC Pharma Group

if the latter is merely a trade description.

Mention:

• Legal name
• Constitution
• Registered/business address
• GSTIN
• Drug licence, where relevant
• Authorized signatory

Verify Drug Licences Before Signing

A pharmaceutical distributor should hold licences appropriate to the activities and categories of medicines handled.

Wholesale drug licensing under the Drugs Rules commonly involves Forms 20B/21B and other applicable forms according to the products involved. CDSCO also notified amendments on February 16, 2026 affecting conditions attached to Forms 20B, 20BB, 21B and 21BB, including competent-person requirements.

The agreement should require the distributor to:

• Maintain valid licences.
• Notify the company of suspension/cancellation.
• Supply renewed licence copies.
• Store medicines only at authorized premises.
• Follow applicable prescription-drug restrictions.

Do not rely on a licence copy collected five years earlier.

Important Documents to Obtain

A company may collect copies of:

• Drug licence
• GST registration
• PAN
• Firm/company registration
• Authorized-signatory proof
• Address proof
• Bank details
• Udyam details, if relevant
• Cancelled cheque
• Distributor constitution documents

Where credit is given, additional financial checks may be appropriate.

1. Territory Clause

The territory clause is one of the most important provisions.

Avoid vague language such as:

“North India monopoly.”

Instead define territory precisely.

Example:

District Karnal, Haryana, excluding institutional tenders and government supplies.

Or:

Districts Karnal and Kurukshetra, subject to the exclusions in Annexure B.

Define whether rights include:

• Retail sales
• Hospital supply
• Institutional business
• Government tender
• Online sales
• Sub-distribution
• Export

Otherwise both parties may interpret “monopoly” differently.

2. Exclusive vs Non-Exclusive Rights

The agreement should expressly state whether appointment is:

Exclusive

The company agrees not to appoint another franchise partner within the defined scope, subject to stated exceptions.

Non-Exclusive

The company may appoint additional distributors.

Conditional Exclusive

The distributor receives exclusivity only while fulfilling agreed conditions.

For PCD business, conditional exclusivity is often commercially safer.

For example:

Monopoly rights continue subject to:

• Minimum quarterly sales
• Timely payment
• Adequate product coverage
• Compliance with licence conditions
• No diversion outside territory

Competition-Law Consideration

Exclusive distribution arrangements are vertical agreements.

The Competition Commission of India specifically identifies exclusive distribution arrangements and resale price maintenance among vertical arrangements under Section 3(4) of the Competition Act. Such arrangements may be examined for their effect on competition.

The Indian Contract Act also contains Section 27 dealing with agreements in restraint of trade.

This does not mean that every territorial PCD arrangement is prohibited. It means overly broad exclusivity, resale controls and post-termination restraints should be drafted carefully rather than copied from a generic internet template.

3. Minimum Business Clause

Do not write:

“Distributor must provide good business.”

Define measurable requirements.

Example:

• First-quarter minimum purchase: ₹____
• Thereafter quarterly purchase: ₹____
• Performance reviewed every three months
• Company may reduce or withdraw exclusivity after written notice if target is not achieved

Targets can also be based on:

• Product range
• Active retailers
• Secondary sales
• Territory development

Avoid Automatic Cancellation After One Bad Month

PCD sales fluctuate.

A better system may provide:

Review → Written warning → Improvement period → Territory restructuring

This is commercially more practical than immediately terminating monopoly rights.

4. Product Annexure

Attach a separate product list.

Include:

• Brand name
• Composition
• Dosage form
• Pack size
• Net rate
• MRP, where relevant
• GST
• Scheme
• Product status

Use an annexure so that new products can be added without rewriting the complete agreement.

5. Price and Net Rate Clause

A clause can provide that:

• Current rates appear in the price list.
• GST is charged as legally applicable.
• Freight terms are stated separately.
• Rates may be revised by written/electronic notice.
• Accepted purchase orders are governed by the agreed price applicable to that order.
• Scheduled formulations remain subject to applicable NPPA requirements.

NPPA continues to administer the Drugs (Prices Control) Order, 2013 and ceiling-price controls for scheduled formulations.

Should the Agreement Fix PTR and PTS?

It may contain commercial guidance, but avoid poorly drafted clauses forcing unlawful resale pricing.

The Competition Commission identifies resale price maintenance as a vertical restraint subject to competition-law scrutiny.

For price-controlled medicines, applicable NPPA requirements must also be followed.

Therefore, have price-control language legally reviewed where necessary.

6. Purchase Order Clause

Specify how orders will be placed.

For example:

• Email
• ERP
• Authorized WhatsApp number
• Purchase-order document
• Distributor portal

The agreement can state that an order becomes binding only after acceptance by the company.

Include provisions for:

• MOQ
• Case quantity
• Product availability
• Price confirmation
• Dispatch schedule

7. Payment Clause

Clearly specify:

Advance Model

100% payment before dispatch.

Partial Advance

Example:

50% advance and balance before dispatch.

Credit Model

Example:

30-day credit subject to approved credit limit.

Also specify:

• Bank account
• Credit limit
• Interest/delayed-payment consequences where legally valid
• Cheque dishonour
• Set-off
• Outstanding settlement

Never leave credit terms only to verbal understanding.

8. GST and Tax Clause

State:

• Whether quoted prices exclude or include GST
• Who issues invoices
• Responsibility for GST compliance
• Credit-note treatment
• Scheme treatment
• Tax consequences of returns

If tax law changes, the agreement should permit corresponding invoice adjustments according to applicable law.

9. Delivery Clause

Define:

• Dispatch location
• Delivery location
• Transporter selection
• Freight responsibility
• Expected dispatch period
• Insurance
• Proof of delivery

Avoid unconditional promises such as:

“Delivery always within three days.”

Use:

“Subject to stock availability, payment clearance, force majeure and agreed dispatch schedule.”

10. Risk in Transit

The Sale of Goods Act provides that risk generally passes with property unless the parties agree otherwise.

The contract should specifically state:

• When title passes
• When transit risk passes
• Who insures the goods
• Who files transporter claims
• Documentation required for shortages
• Time for reporting damage

For example:

Transit-risk arrangement should be defined separately from product-quality responsibility.

A damaged box in transit and a manufacturing defect are not the same issue.

11. Storage Conditions

The franchise partner should agree to store products according to:

• Product label
• Drug Rules
• Manufacturer instructions
• Temperature requirements

Particularly relevant for:

• Insulin
• Vaccines
• Biologicals
• Other cold-chain products

Improper distributor storage should not become the manufacturer’s responsibility if proper product was supplied and the deterioration resulted from documented mishandling after transfer of risk.

12. Expiry and Near-Expiry Clause

“Expiry will be responsibility of second party. Products once sold will not be taken back.”

is commercially possible as a narrow expiry policy but should not be drafted as an absolute exclusion.

Separate:

Commercial Expiry

Unsold stock approaching normal expiry.

Quality Defect

Product fails specification.

Regulatory Recall

Authority/company withdraws product.

Transit Damage

Goods damaged while being transported.

Wrong Supply

Incorrect item or quantity supplied.

These situations require different treatment.

Example Expiry Policy

You may specify:

• Minimum remaining shelf life at dispatch
• Period for raising expiry claims
• Whether replacement/credit is allowed
• Required invoice and batch proof
• Maximum claim percentage
• Exclusions for damaged/poorly stored stock

Avoid accepting open-ended returns without documentation.

13. Product Recall Clause

This is essential.

The franchisee should agree to:

• Immediately stop sale of affected batch.
• Segregate stock.
• Inform downstream customers where instructed.
• Provide batch-wise distribution records.
• Return or destroy stock as instructed.
• Cooperate with authorities.

A recall obligation should override an ordinary “no returns” clause.

14. Quality Complaint Clause

Define the complaint process for issues such as:

• Broken tablets
• Leakage
• Colour variation
• Failed dissolution
• Short fill
• Damaged strips
• Suspected contamination
• Suspected counterfeit product

Require:

• Product name
• Batch
• Invoice
• Photographs where relevant
• Retained sample where available
• Complaint date
• Quantity affected

The manufacturer/Quality Unit should investigate according to its quality system.

15. Certificate of Analysis

That can be contractually agreed, particularly for institutional or specialized business, but it is not necessary to prescribe it mechanically for every ordinary PCD transaction.

A more flexible provision can state that:

Batch CoA or quality documentation will be provided where contractually agreed, legally required or reasonably required for investigation/tender purposes.

16. Independent Laboratory Testing

Independent Laboratory testing is useful where the parties disagree on quality.

Improve it by specifying:

• Mutually agreed laboratory
• NABL/accredited/approved status where appropriate
• Sampling procedure
• Sealed sample
• Chain of custody
• Cost allocation
• Effect of official regulatory testing

Private contractual testing should not override statutory test results or regulatory authority.

17. Marketing and Promotion Clause

UCPMP 2024 is currently described by the Department of Pharmaceuticals as a mandatory code, and its official FAQ says it applies to pharmaceutical companies, their employees, agents and third parties acting on their behalf.

Therefore, the agreement should require the PCD partner to comply with applicable rules governing:

• Promotional claims
• Samples
• Gifts
• Hospitality
• Healthcare-professional interaction
• Promotional literature
• Digital advertising

The franchise partner should not be allowed to create exaggerated medical claims simply because it paid for the brochure itself.

Approval of Promotional Material

A useful clause is:

No promotional literature, digital advertisement, social-media creative or product claim using the company’s products or trademarks may be released without prior written approval where approval is required under the company’s promotional-control procedure.

This protects both parties.

18. Medical Samples

Define:

• Who supplies samples
• Quantity
• Cost
• Records
• Labelling
• Distribution restrictions

Do not treat free samples as ordinary trade stock.

19. Trademark Ownership

This is one of the most important clauses.

The agreement should state:

• Who owns each trademark
• Whether registration is pending
• Whether distributor has only limited permission to use it
• Territory of permitted use
• Duration of permission
• Use after termination
• Ownership of artwork and logos

The Trade Marks Act gives a registered proprietor exclusive rights, while “permitted use” can arise through consent contained in a written agreement subject to applicable conditions.

Do Not Allow Franchisee to Register the Company’s Brand

The contract should generally prohibit a franchise partner from filing:

• Trademark
• Domain
• Social-media name
• Company name

that improperly incorporates or claims ownership over the principal’s protected brand.

But responsibility for conducting the original trademark search should also remain clear.

20. What If the Brand Infringes Someone Else’s Trademark?

Agreement may place the entire responsibility on the first party.

A better clause should distinguish between:

Company-created trademark

Principal may indemnify the distributor for authorized use, subject to stated conditions.

Distributor modifies the mark

Distributor bears responsibility for unauthorized changes.

Distributor independently adopts a similar mark

Distributor bears its own risk.

Trademark infringement can arise where an unauthorized identical or deceptively similar mark creates the relevant likelihood of confusion.

21. Sub-Distributor Appointment

State whether the franchisee may appoint:

• Stockists
• Distributors
• Retailers
• Sub-franchisees

If allowed, define:

• Licence verification
• Territory restrictions
• Company’s approval
• Liability
• UCPMP compliance
• Trademark use

A PCD partner should not be able to sell the territory to another party unless the contract permits it.

22. No Diversion Outside Territory

The agreement can restrict active distribution outside the allocated territory.

However, exclusivity and market restrictions should be drafted with competition-law considerations in mind. CCI identifies exclusive distribution arrangements among vertical restraints subject to Section 3(4) analysis.

Avoid extremely broad language extending far beyond what is necessary to operate the franchise.

23. Confidentiality Clause

Protect:

• Net rates
• Customer information
• Product pipeline
• Business plans
• Sales data
• Unreleased products
• Distributor lists
• Artwork
• Marketing strategy

Specify how long confidentiality continues after termination.

24. Personal Data Clause

Modern franchise businesses often exchange personal data involving:

• Sales personnel
• Doctors’ contact information
• Distributor contacts
• Leads
• Customer representatives

India now has the Digital Personal Data Protection Act, 2023 and the Digital Personal Data Protection Rules, 2025, with provisions being brought into force on a phased timeline from November 13, 2025.

The agreement should therefore consider:

• Lawful data use
• Data-security responsibilities
• Sharing restrictions
• Deletion/return after termination

depending on the actual data-processing activities.

25. Records and Audit

The agreement may require the franchise partner to maintain:

• Purchase records
• Sale records
• Batch records
• Stock
• Expiry
• Complaints
• Recall records
• Promotional approvals

The company may reserve reasonable audit rights relevant to:

• Regulatory compliance
• Brand use
• Territory
• Stock
• Recall

Avoid unlimited intrusive audit powers unrelated to the agreement.

26. Indemnity Clause

Indemnity allocates responsibility when one party’s breach causes loss to the other.

Examples include:

Company Responsibility

May include, depending on negotiated terms:

• Unauthorized use of third-party intellectual property supplied by company
• Manufacturing defect
• Misrepresentation by company
• Regulatory non-compliance attributable to company

Distributor Responsibility

May include:

• Sale without required licence
• Improper storage
• Unauthorized promotion
• Territory diversion
• Trademark misuse
• Tax violation caused by distributor
• Unauthorized product modification

Avoid one-line unlimited indemnities.

Define:

• Type of loss
• Notice procedure
• Defence of claims
• Liability caps
• Exclusions

through legal review.

27. Limitation of Liability

A commercial agreement can define liability, but contractual limitations should not be drafted as an attempt to eliminate mandatory statutory responsibilities.

For example, a clause saying:

“Manufacturer is never responsible for product quality after sale.”

would be problematic as a general statement.

The agreement should instead allocate controllable commercial risks while preserving applicable legal obligations.

28. Duration of Agreement

There is no compulsory three-year duration.

The parties may choose:

• One year
• Two years
• Three years
• Longer fixed period
• Renewable arrangement

Your original template uses three years with another three-year renewal. That is one commercial option, not a legal rule.

A practical arrangement might be:

Initial term: 2 years

Performance review: every 6 months

Renewal: by written agreement

29. Termination Clause

Specify termination:

Without Cause

Example: 30/60/90 days’ notice.

For Cause

Immediate or shorter termination for:

• Drug-licence cancellation
• Fraud
• Counterfeit activity
• Serious regulatory breach
• Non-payment
• Trademark misuse
• Diversion
• Repeated target failure
• Insolvency

30. Consequences of Termination

Specify what happens to:

• Outstanding invoices
• Unsold stock
• Near-expiry goods
• Promotional materials
• Confidential documents
• Territory rights
• Trademark permission
• Website/social accounts
• Pending purchase orders

Termination should not leave these issues unresolved.

31. Force Majeure

A clause may cover events beyond reasonable control such as:

• Natural disasters
• War
• Government restrictions
• Major transport interruption
• Epidemics/pandemics
• Industrial disruption

It should specify:

• Notification
• Mitigation
• Suspension of obligations
• Long-stop termination period

Do not use force majeure to excuse ordinary financial difficulty or poor planning.

32. Dispute Resolution

The dispute resolution will be settled under the Arbitration and Conciliation Act, 1996. This remains a common approach; the Act continues to govern domestic and international commercial arbitration and enforcement of awards.

A stronger arbitration clause should specify:

• Number of arbitrators
• Appointment mechanism
• Seat of arbitration
• Venue
• Language
• Governing law

Do not simply write:

“Any dispute will go to arbitration in India.”

Seat vs Venue

These can have different legal consequences.

A lawyer should align:

• Arbitration seat
• Court jurisdiction
• Governing law

rather than copying different cities into different clauses.

33. Notices

A present-day clause may permit notices through:

• Registered post
• Recognized courier
• Designated official email

Define when an electronic notice is considered received.

Can a Pharma Franchise Agreement Be Signed Electronically?

Potentially yes.

The Information Technology Act recognizes electronic records, electronic signatures and the validity of contracts formed through electronic means.

However, proper:

• Stamp duty
• Signature authority
• Record retention
• State-specific requirements

should still be checked.

Is Stamp Paper Compulsory?

The better answer is:

Applicable stamp duty should be paid according to the nature of the instrument and the relevant State stamp law.

The Indian Stamp Act deals with instruments chargeable with stamp duty, but states have their own amendments/schedules and rates.

Therefore, there is no universal answer such as:

“Every pharma franchise agreement must be on ₹100 stamp paper.”

Check the state where the agreement is executed and the applicable instrument classification.

Are Two Witnesses Compulsory?

Not universally for every ordinary commercial distribution agreement.

Witnesses may nevertheless be useful for evidentiary purposes and may be required in particular transaction/document contexts.

Do not claim “two witnesses are legally compulsory” without checking the specific instrument and state law.

Is Notarization Compulsory?

Not automatically for every PCD distribution agreement.

Parties may still choose notarization for additional evidentiary formality.

Stamping, notarization and registration are different concepts.

Suggested Annexures

A well-structured agreement can keep frequently changing commercial information outside the main contract.

Annexure A

Products and compositions

Annexure B

Territory

Annexure C

Price list

Annexure D

Sales targets

Annexure E

Promotional support

Annexure F

Expiry/return policy

Annexure G

Authorized contacts and bank details

This makes future changes easier.

Recommended Structure of a Modern Pharma Franchise Agreement

A modern agreement can follow this order:

1. Title
2. Date
3. Parties
4. Recitals/background
5. Definitions
6. Appointment
7. Territory
8. Exclusivity
9. Products
10. Orders
11. Pricing
12. GST
13. Payment
14. Credit limit
15. Delivery
16. Risk and insurance
17. Storage
18. Licences
19. Quality
20. Recall
21. Expiry/returns
22. Complaints
23. Promotional activity
24. UCPMP compliance
25. Trademark and IP
26. Confidentiality
27. Personal data
28. Sub-distributors
29. Sales targets
30. Records/audit
31. Representations and warranties
32. Indemnity
33. Liability
34. Force majeure
35. Term
36. Termination
37. Consequences of termination
38. Notices
39. Dispute resolution
40. Arbitration
41. Governing law
42. Entire agreement
43. Amendments
44. Severability
45. Signatures
46. Annexures

Sample Short-Form Framework

DISTRIBUTION AND MARKETING AGREEMENT

This Agreement is entered into on __________ between [Pharma Company Legal Name], having its registered office at __________ (“Company”), and [Distributor Legal Name], having its business premises at __________ (“Distributor”).

Appointment

The Company appoints the Distributor to promote and distribute the products listed in Annexure A within the territory specified in Annexure B, subject to the terms of this Agreement.

Territory

The Distributor shall operate only within __________. Institutional, government, online or other excluded channels shall be governed by Annexure B.

Exclusivity

The appointment shall be [exclusive/non-exclusive/conditional exclusive]. Where exclusivity is granted, continuation shall be subject to agreed sales, payment and compliance requirements.

Licences

Each party shall maintain all licences and registrations required for the activities performed by it and shall promptly notify the other party of any suspension, cancellation or material regulatory restriction.

Products and Prices

Products and current rates shall be listed in Annexure A/C. Prices may be revised in accordance with the agreed notice procedure and applicable tax and price-control laws.

Payment

Payment shall be made on __________ terms. Any approved credit shall remain subject to the Distributor’s credit limit and payment performance.

Delivery

Orders shall be supplied subject to acceptance, availability and agreed dispatch terms. Freight, insurance and the point of transfer of risk shall be specified in the applicable purchase order or Annexure.

Storage

The Distributor shall store, handle and transport products according to their approved storage conditions and applicable legal requirements.

Quality and Recall

The Distributor shall promptly report suspected quality defects and cooperate fully with batch recalls. Recalled or defective products shall be handled under the Company’s applicable quality and recall procedures.

Promotion

The Distributor shall promote products only in accordance with applicable law, UCPMP requirements and approved product information. Unauthorized claims or alterations to approved promotional content are prohibited.

Trademark

All trademarks and associated intellectual property shall remain the property of their respective owners. The Distributor receives only a limited permission to use Company marks for authorized distribution and promotion during the term.

Sales Performance

The parties may agree minimum purchase or market-development targets in Annexure D. Failure to meet them may lead to review or modification of exclusive territory after the agreed notice/cure process.

Termination

Either party may terminate according to the notice period stated herein. Immediate termination may apply for serious licence, fraud, counterfeit, regulatory, payment or trademark breaches.

Arbitration

Disputes not resolved amicably shall be referred to arbitration under the Arbitration and Conciliation Act, 1996 in accordance with the agreed seat, appointment procedure and language.

Governing Law

The Agreement shall be governed by the laws of India.

For Company: __________________

For Distributor: _______________

This short form is only an illustrative clause framework, not a substitute for a state-specific legal agreement.

Common Mistakes in Pharma Franchise Agreements

Avoid:

• Writing only “monopoly basis” without defining territory
• Giving lifetime monopoly
• No sales-performance condition
• No product annexure
• No price-revision mechanism
• No drug-licence verification
• No expiry policy
• Absolute “no returns” language
• Absolute “no liability after dispatch”
• No recall clause
• No storage clause
• Allowing unrestricted promotional claims
• Ignoring UCPMP
• No trademark ownership clause
• Allowing distributor to register brand names
• Mandatory resale price clauses without competition-law review
• No confidentiality
• No data protection
• No consequences of termination
• No arbitration seat
• Automatically using a three-year agreement

Practical Checklist Before Signing

Before execution, verify:

• Legal names of both parties
• Constitution of both entities
• Drug licences
• GST details
• Authorized signatories
• Product list
• Exact territory
• Exclusivity conditions
• Minimum sales
• Net rates
• Price-revision procedure
• GST and freight
• Payment/credit terms
• Delivery terms
• Transit-risk point
• Storage responsibility
• Expiry policy
• Recall procedure
• Quality complaint process
• Promotion/UCPMP requirements
• Trademark ownership
• Sub-distributor rights
• Confidentiality
• Term
• Termination
• Closing-stock treatment
• Arbitration
• Court jurisdiction
• Applicable stamp duty
• Signatures

Final Answer

A Pharma Franchise Distribution and Marketing Agreement is a written commercial agreement that defines the relationship between a pharma company and its PCD/franchise distributor.

Its most important clauses are not merely the names and signatures. It should clearly define:

territory + monopoly conditions + products + licences + rates + payments + delivery + expiry + quality + recalls + promotional compliance + trademarks + termination + dispute resolution.

At present, three additional areas deserve particular attention.

First, CDSCO’s marketer rules mean that a formal manufacturer–marketer relationship should not be confused with a simple distributorship arrangement.

Second, UCPMP 2024 applies not only to pharmaceutical companies but also to employees, agents and third parties acting on their behalf, making promotional-compliance clauses particularly important for PCD relationships.

Third, monopoly and resale-control clauses should be drafted carefully because exclusive distribution and resale price maintenance are recognized categories of vertical agreements under Indian competition law.

A strong agreement should protect the company without unfairly transferring every possible risk to the distributor, and it should protect the distributor without permanently blocking the company from an underperforming territory.

Looking for Ayurvedic Franchise or Distribution Opportunities?

Looking to start an Ayurvedic franchise, become a distributor, or launch your own herbal product range?

Elzac Herbal India offers:

• Ayurvedic & Herbal Product Range
• Franchise & Distribution Opportunities
• Third-Party Manufacturing
• Product Development Support
• Marketing Guidance
• PAN India Business Opportunities

Whether you are an entrepreneur, retailer, distributor, or healthcare professional, our team can help you explore the right business opportunity in the growing Ayurvedic sector.

Contact us today to discuss ayurvedic franchise, distribution, or third-party manufacturing opportunities.